ROGER I LANE
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- SOLVANG, CA
- NPI
- 1154424240
- Received
- $3,031 in 22 records, 2019 to 2025 ($267 general, $2,763 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 4 | $72 |
| 2020 | General payment | 2 | $40 |
| 2020 | Research payment | 1 | $295 |
| 2019 | General payment | 8 | $154 |
| 2019 | Research payment | 7 | $2,468 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| F. Hoffmann-La Roche AG | 8 | $2,763 | 2019–2020 |
| Amgen Inc. | 3 | $65 | 2019–2025 |
| PFIZER INC. | 2 | $44 | 2019–2020 |
| Janssen Pharmaceuticals, Inc | 2 | $40 | 2019–2020 |
| ABBVIE INC. | 2 | $33 | 2025 |
| Esperion Therapeutics, Inc. | 1 | $20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 | 2019 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $15 | 2019 |
| SANOFI PASTEUR INC. | 1 | $11 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 8 | $2,763 |
| Food and Beverage | 14 | $267 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-03 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | Esperion Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-10-10 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-29 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2020-03-31 | F. Hoffmann-La Roche AG | $295 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2020 |
| 2020-03-06 | Janssen Pharmaceuticals, Inc | $18 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-02-07 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2020 | |
| 2019-12-31 | F. Hoffmann-La Roche AG | $366 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2019 |
| 2019-12-31 | F. Hoffmann-La Roche AG | $281 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2019 |
| 2019-10-11 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2019 | |
| 2019-09-30 | F. Hoffmann-La Roche AG | $812 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2019 |
| 2019-09-30 | F. Hoffmann-La Roche AG | $331 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2019 |
| 2019-09-30 | F. Hoffmann-La Roche AG | $206 | Research payment | In-kind items and services | Drug | A SAFETY, TOLERABILITY AND BIOMARKER UPDATE FROM AN ONGOING OPEN-LABEL EXTENSION STUDY OF RG6042 IN ADULTS WITH EARLY MA | 2019 |
| 2019-08-09 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2019 | |
| 2019-07-26 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2019 | |
| 2019-07-12 | SANOFI PASTEUR INC. | $11 | Food and Beverage | In-kind items and services | FLUBLOK QUADRIVALENT Drug, VACCINES | 2019 | |
| 2019-06-30 | F. Hoffmann-La Roche AG | $206 | Research payment | In-kind items and services | Drug | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 I | 2019 |
| 2019-06-14 | Janssen Pharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-04-05 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-03-31 | F. Hoffmann-La Roche AG | $263 | Research payment | In-kind items and services | Drug | AN UPDATE FROM AN ONGOING OPEN-LABEL EXTENSION OLE STUDY INVESTIGATING RG6042 HUNTINGTIN ANTISENSE OLIGONUCLEOTIDE ASO I | 2019 |
| 2019-02-08 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2019 | |
| 2019-01-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | SPIRIVA Drug, RESPIRATORY | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Solvang, CA, county Santa Barbara County, CA, state California; placed by its city name.
| Measure | Place (city or town) Solvang, CA | County Santa Barbara County, CA | State California |
|---|---|---|---|
| Population B01003 | 6,034 | 443,701 | 39,287,377 |
| Population, 2020 census P1 | 6,126 | 448,229 | 39,538,223 |
| Median age B01002 | 54.2 | 34.6 | 37.9 |
| Under 18 B01001 | 13.4% | 22.4% | 22.0% |
| 65 and over B01001 | 33.4% | 16.6% | 15.7% |
| Households B11001 | 2,726 | 149,608 | 13,548,091 |
| Foreign born B05002 | 21.1% | 22.2% | 27.0% |
| Median household income B19013 | $109,091 | $98,161 | $99,122 |
| Median family income B19113 | $141,167 | $112,855 | $113,346 |
| Per capita income B19301 | $71,717 | $48,028 | $49,513 |
| Poverty rate B17001 | 11.3% | 14.7% | 12.0% |
| Unemployment rate B23025 | 1.8% | 6.4% | 6.6% |
| Civilian labor force B23025 | 3,074 | 219,992 | 20,068,466 |
| Mean commute (minutes) B08013 | 29.2 | 20.8 | 28.7 |
| Bachelor's degree or higher B15003 | 38.2% | 36.8% | 37.1% |
| Housing units B25001 | 2,813 | 160,592 | 14,644,735 |
| Owner-occupied B25003 | 57.0% | 52.4% | 55.9% |
| Renters B25003 | 43.0% | 47.6% | 44.1% |
| Median home value B25077 | $949,600 | $790,700 | $734,700 |
| Median gross rent B25064 | $1,666 | $2,131 | $2,036 |
| White, not Hispanic B03002 | 61.1% | 40.6% | 33.8% |
| Black B03002 | 2.7% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 25.4% | 48.2% | 40.2% |
| Asian B03002 | 2.9% | 5.2% | 15.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Solvang, CA.
Comments